45 results on '"Eto, Masatoshi"'
Search Results
2. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
- Author
-
Grünwald, Viktor, Powles, Thomas, Kopyltsov, Evgeny, Kozlov, Vadim, Alonso-Gordoa, Teresa, Eto, Masatoshi, Hutson, Thomas, Motzer, Robert, Winquist, Eric, Maroto, Pablo, Keam, Bhumsuk, Procopio, Giuseppe, Wong, Shirley, Melichar, Bohuslav, Rolland, Frederic, Oya, Mototsugu, Rodriguez-Lopez, Karla, Saito, Kenichi, McKenzie, Jodi, and Porta, Camillo
- Published
- 2023
- Full Text
- View/download PDF
3. Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
- Author
-
Blas, Leandro, Shiota, Masaki, Nagakawa, Shohei, Tsukahara, Shigehiro, Matsumoto, Takashi, Lee, Ken, Monji, Keisuke, Kashiwagi, Eiji, Inokuchi, Junichi, and Eto, Masatoshi
- Published
- 2023
- Full Text
- View/download PDF
4. Initial experience with vibegron for the treatment of neurogenic lower urinary tract storage dysfunction in patients with spinal cord injury
- Author
-
Lee, Ken, Takahashi, Ryosuke, Imada, Kenjiro, Okabe, Ayami, Kajioka, Shunichi, Kashiwagi, Eiji, Shiota, Masaki, Inokuchi, Junichi, and Eto, Masatoshi
- Published
- 2022
- Full Text
- View/download PDF
5. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
- Author
-
Chikamatsu, Sotaro, Shiota, Masaki, Yamada, Shigetomo, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, and Eto, Masatoshi
- Published
- 2022
- Full Text
- View/download PDF
6. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
- Author
-
Yamada, Shigetomo, Shiota, Masaki, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, and Eto, Masatoshi
- Published
- 2022
- Full Text
- View/download PDF
7. Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
- Author
-
Matsumoto, Takashi, Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, and Eto, Masatoshi
- Published
- 2021
- Full Text
- View/download PDF
8. Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
- Author
-
Kashiwagi, Eiji, Shiota, Masaki, Masaoka, Hiroyuki, Imada, Kenjiro, Monji, Keisuke, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, and Eto, Masatoshi
- Published
- 2020
- Full Text
- View/download PDF
9. Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
- Author
-
Hirata, Yu, Shiota, Masaki, Kobayashi, Takeshi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, and Eto, Masatoshi
- Published
- 2019
- Full Text
- View/download PDF
10. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
- Author
-
Motzer, Robert J., Choueiri, Toni K., Hutson, Thomas, Young Rha, Sun, Puente, Javier, Lalani, Aly-Khan A., Winquist, Eric, Eto, Masatoshi, Basappa, Naveen S., Tannir, Nizar M., Vaishampayan, Ulka, Bjarnason, Georg A., Oudard, Stéphane, Grünwald, Viktor, Burgents, Joseph, Xie, Ran, McKenzie, Jodi, and Powles, Thomas
- Published
- 2024
- Full Text
- View/download PDF
11. Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
- Author
-
Akitake, Naoko, Shiota, Masaki, Obata, Hirofumi, Takeuchi, Ario, Kashiwagi, Eiji, Imada, Kenjiro, Kiyoshima, Keijiro, Inokuchi, Junichi, Tatsugami, Katsunori, and Eto, Masatoshi
- Published
- 2018
- Full Text
- View/download PDF
12. Role of K+ channels in regulating spontaneous activity in the muscularis mucosae of guinea pig bladder
- Author
-
Lee, Ken, Isogai, Ayu, Antoh, Minori, Kajioka, Shunichi, Eto, Masatoshi, and Hashitani, Hikaru
- Published
- 2018
- Full Text
- View/download PDF
13. Combination of ALDH2 and ADH1B polymorphisms is associated with smoking initiation: A large-scale cross-sectional study in a Japanese population
- Author
-
Masaoka, Hiroyuki, Ito, Hidemi, Gallus, Silvano, Watanabe, Miki, Yokomizo, Akira, Eto, Masatoshi, and Matsuo, Keitaro
- Published
- 2017
- Full Text
- View/download PDF
14. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
- Author
-
Choueiri, Toni K, Eto, Masatoshi, Motzer, Robert, De Giorgi, Ugo, Buchler, Tomas, Basappa, Naveen S, Méndez-Vidal, María José, Tjulandin, Sergei, Hoon Park, Se, Melichar, Bohuslav, Hutson, Thomas, Alemany, Carlos, McGregor, Bradley, Powles, Thomas, Grünwald, Viktor, Alekseev, Boris, Rha, Sun Young, Kopyltsov, Evgeny, Kapoor, Anil, and Alonso Gordoa, Teresa
- Subjects
- *
RENAL cell carcinoma , *SUNITINIB , *ENDOTHELIAL growth factors , *PEMBROLIZUMAB , *KARNOFSKY Performance Status - Abstract
In the primary analysis of the CLEAR study, lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma (data cutoff Aug 28, 2020). We aimed to assess overall survival based on 7 months of additional follow-up. This is a protocol-prespecified updated overall survival analysis (data cutoff March 31, 2021) of the open-label, phase 3, randomised CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy for renal cell carcinoma, including anti-vascular endothelial growth factor therapy, or any systemic investigational anticancer drug, were eligible for inclusion from 200 sites (hospitals and cancer centres) across 20 countries. Patients were randomly assigned (1:1:1) to receive lenvatinib (20 mg per day orally in 21-day cycles) plus pembrolizumab (200 mg intravenously every 21 days; lenvatinib plus pembrolizumab group), lenvatinib (18 mg per day orally) plus everolimus (5 mg per day orally; lenvatinib plus everolimus group [not reported in this updated analysis]) in 21-day cycles, or sunitinib (50 mg per day orally, 4 weeks on and 2 weeks off; sunitinib group). Eligible patients were at least 18 years old with a Karnofsky performance status of 70 or higher. A computer-generated randomisation scheme was used, and stratification factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint was progression-free survival assessed by independent imaging review according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). In this Article, extended follow-up analyses for progression-free survival and protocol-specified updated overall survival data are reported for the intention-to-treat population. No safety analyses were done at this follow-up. This study is closed to new participants and is registered with ClinicalTrials.gov , NCT02811861. Between Oct 13, 2016, and July 24, 2019, 1417 patients were screened for inclusion in the CLEAR trial, of whom 1069 (75%; 273 [26%] female, 796 [74%] male; median age 62 years [IQR 55–69]) were randomly assigned: 355 (33%) patients (255 [72%] male and 100 [28%] female) to the lenvatinib plus pembrolizumab group, 357 (33%) patients (275 [77%] male and 82 [23%] female) to the sunitinib group, and 357 (33%) patients to the lenvatinib plus everolimus group (not reported in this updated analysis). Median follow-up for progression-free survival was 27·8 months (IQR 20·3–33·8) in the lenvatinib plus pembrolizumab group and 19·4 months (5·5–32·5) in the sunitinib group. Median progression-free survival was 23·3 months (95% CI 20·8–27·7) in the lenvatinib plus pembrolizumab group and 9·2 months (6·0–11·0) in the sunitinib group (stratified hazard ratio [HR] 0·42 [95% CI 0·34–0·52]). Median overall survival follow-up was 33·7 months (IQR 27·4–36·9) in the lenvatinib plus pembrolizumab group and 33·4 months (26·7–36·8) in the sunitinib group. Overall survival was improved with lenvatinib plus pembrolizumab (median not reached [95% CI 41·5–not estimable]) versus sunitinib (median not reached [38·4–not estimable]; HR 0·72 [95% CI 0·55–0·93]). Efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful with extended follow-up. These results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma. Eisai and Merck Sharp & Dohme. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.
- Author
-
Nakai, Yasutomo, Takeuchi, Ario, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Sugimoto, Mikio, Eto, Masatoshi, Minami, Keita, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Miyauchi, Yasuyuki, Ohba, Kojiro, Kashiwagi, Akira, Murakami, Masaya, Sazuka, Tomokazu, Yasumoto, Hiroaki, Morizane, Shuichi, Kawasaki, Yoshihide, and Morooka, Daichi
- Published
- 2021
- Full Text
- View/download PDF
16. NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide.
- Author
-
Shiota, Masaki, Ushijima, Miho, Tsukahara, Shigehiro, Nagakawa, Shohei, Blas, Leandro, Takamatsu, Dai, Kobayashi, Satoshi, Matsumoto, Takashi, Inokuchi, Junichi, and Eto, Masatoshi
- Abstract
This study investigated cellular mechanisms in steroidogenesis responsible for treatment resistance to the novel antiandrogen agent darolutamide in prostate cancer. HSD3B1 was overexpressed in darolutamide-resistant cells and induced by darolutamide treatment and AR knockdown. Inversely, HSD3B1 knockdown increased cellular sensitivity to darolutamide. Similarly, its upstream regulator NR5A2 was up-regulated in darolutamide-resistant cells and induced by darolutamide treatment and AR knockdown. Inversely, NR5A2 knockdown and NR5A2 inhibitor ML180 decreased expression of various steroidogenic enzymes including HSD3B1, leading to increased cellular sensitivity to darolutamide. The NR5A2/HSD3B1 pathway promoted cellular resistance to darolutamide and targeting NR5A2/HSD3B1 pathway is a promising therapeutic strategy to overcome darolutamide resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. The tail nick augments Aeromonas sobria serine protease (ASP) activity in plasma through retarding inhibition by α2-macroglobulin
- Author
-
Murakami, Yoji, Wada, Yoshihiro, Kobayashi, Hidetomo, Hasegawa, Makoto, Okamoto, Keinosuke, Eto, Masatoshi, and Imamura, Takahisa
- Published
- 2012
- Full Text
- View/download PDF
18. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
- Author
-
Takeuchi, Ario, Eto, Masatoshi, Tatsugami, Katsunori, Shiota, Masaki, Yamada, Hisakata, Kamiryo, Yoriyuki, Dejima, Takashi, Kashiwagi, Eiji, Kiyoshima, Keijiro, Inokuchi, Junichi, Takahashi, Ryosuke, Yokomizo, Akira, Ohara, Naoya, and Yoshikai, Yasunobu
- Subjects
- *
ANTINEOPLASTIC agents , *BCG vaccines , *INTERLEUKIN-15 , *CHIMERIC proteins , *BLADDER cancer treatment , *NEUTROPHIL immunology , *CHEMOKINES , *THERAPEUTICS - Abstract
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is used for the treatment of bladder cancer. The recruitment of neutrophlis to the bladder after BCG instillation exerts anti-tumor activity against bladder tumor. We have recently demonstrated that interleukin (IL)-17A produced by γδ T cells played a role in the recruitment of neutrophlis to the bladder after BCG instillation. IL-15 is known to play an important role in neutrophil migration during inflammation. We previously constructed a recombinant BCG strain expressing the fusion protein of IL-15 and Ag85B (BCG-IL-15) for prevention of Mycobacterium tuberculosis infection. Here we compared the efficacy of the BCG-IL-15 in protection against bladder cancer with that of rBCG-Ag85B (BCG). Six-week-old female C57BL/6 mice were inoculated with MB49 bladder tumor cells in the bladder and subsequently intravesically inoculated with BCG or BCG-IL-15. BCG-IL-15 treatment significantly prolonged survival of mice inoculated with bladder cancer cells compared with BCG treatment. Infiltration of neutrophils was significantly elevated in BCGB-IL-15 treated mice accompanied by increased chemokines (MIP-2 and MIP-1α) in the bladder. Thus, BCG-IL-15 exerted additive effect on Infiltration of neutrophils in the bladder. BCG-IL-15 may be a promising drug for non-muscle invasive bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Upon failure of first-line ADT, should second-line hormonal manipulation without survival benefit data still be used?
- Author
-
Lojanapiwat, Bannakij, Eto, Masatoshi, and Mainwaring, Paul
- Published
- 2015
- Full Text
- View/download PDF
20. Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation.
- Author
-
Takeuchi, Ario, Eto, Masatoshi, Tatsugami, Katsunori, Yamada, Hisakata, Yokomizo, Akira, Shiota, Masaki, Itsumi, Momoe, Inokuchi, Junichi, Kiyoshima, Keijiro, Dejima, Takashi, Imada, Kenjiro, Naito, Seiji, and Yoshikai, Yasunobu
- Subjects
- *
RENAL cancer treatment , *LYMPHOCYTES , *ANTINEOPLASTIC agents , *HOMOGRAFTS , *STEM cell transplantation - Abstract
Background Nonmyeloablative allogeneic stem cell transplantation (SCT) is an option for the treatment of metastatic renal cancer. Mature donor T cells cause graft versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor (GVT) activity associated with this treatment. Hence, the segregation of GVT activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice. Methods The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma with recipient lymphocyte infusion (RLI). Results Regarding the in vivo antitumor effect, there was a significant difference between RLI and no lymphocyte infusion after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with RLI decreased the risk of GVHD as compared with donor lymphocyte infusion. In addition, the acquired immunity against RENCA was clearly observed in RLI-treated mice. Conclusions Our results show that RLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate GVT effects from GVHD by reducing the risk of GVHD. We considered that this was the first report to provide the evidence of nonmyeloablative allogeneic SCT with RLI for the treatment of renal cell carcinoma which never induce complete chimerism. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. STAT3 Polymorphism Can Predict the Response to Interferon-α Therapy in Patients with Metastatic Renal Cell Carcinoma
- Author
-
Eto, Masatoshi, Kamba, Tomomi, Miyake, Hideaki, Fujisawa, Masato, Kamai, Takao, Uemura, Hirotsugu, Tsukamoto, Taiji, Azuma, Haruhito, Matsubara, Akio, Nishimura, Kazuo, Nakamura, Tsuyoshi, Ogawa, Osamu, and Naito, Seiji
- Subjects
- *
CANCER treatment , *RENAL cell carcinoma , *SINGLE nucleotide polymorphisms , *INTERFERONS , *TRANSCRIPTION factors , *METASTASIS , *PATIENTS - Abstract
Abstract: Background: In our 2007 retrospective study, we reported that single nucleotide polymorphisms (SNPs) in the signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3) gene were significantly associated with better response to interferon (IFN)-α in patients with metastatic renal cell carcinoma (mRCC). Objective: To prospectively confirm those results, the Japan Immunotherapy SNPs-Study Group for Kidney Cancer conducted this trial. Design, setting, and participants: In this multicenter, prospective study, 203 eligible patients were enrolled. We evaluated the correlation between the antitumor effects of IFN-α and 11 SNPs (STAT3-2, STAT3-0, SOCS3-1, IL4R-34, PTGS1-3, PTGS1-4, PTGS1-5, PTGS2-12, IRF2-67, ICSBP-38, and TAP2-5) in eight genes in 180 patients who received IFN-α for >12 wk. Interventions: Patients were treated with three doses per week of IFN-α 5 million IU. Outcome measurements and statistical analysis: We analyzed the association of response to IFN-α and overall survival (OS) with genetic polymorphisms using a chi-square test and a logistic regression model. Results and limitations: The response rate of IFN-α was 13.8% (28 of 203 patients; 9 complete responses [CRs], 19 partial responses [PRs]). The CR rate of 4.4% was higher than we expected. Response to IFN-α was not associated with any of the 11 SNPs examined. However, when we assessed patients with CR, PR, and stable disease >24 wk as a group representing those with clinical response, a significant association was observed between STAT3-2 (rs1905341) and the clinical response of IFN-α (p =0.039). Namely, C/C genotype of STAT3-2 was significantly associated with the clinical response of IFN-α and OS. These results were generated in Japanese patients and should be studied in other ethnic groups. Conclusions: This is the first prospective study demonstrating that a STAT3 polymorphism can be a predictive marker for treatment with IFN-α for patients with mRCC. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
22. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer.
- Author
-
Shiota, Masaki, Ushijima, Miho, Tsukahara, Shigehiro, Nagakawa, Shohei, Okada, Tatsunori, Tanegashima, Tokiyoshi, Kobayashi, Satoshi, Matsumoto, Takashi, and Eto, Masatoshi
- Subjects
- *
ANDROGEN receptors , *PEROXISOME proliferator-activated receptors , *PROSTATE cancer , *PEROXISOMES , *OXIDATIVE stress , *CANCER cell proliferation - Abstract
Androgen receptor (AR)-targeting therapy induces oxidative stress in prostate cancer. However, the mechanism of oxidative stress induction by AR-targeting therapy remains unclear. This study investigated the mechanism of oxidative stress induction by AR-targeting therapy, with the aim to develop novel therapeutics targeting oxidative stress induced by AR-targeting therapy. Intracellular reactive oxygen species (ROS) was examined by fluorescence microscopy and flow cytometry analysis. The effects of silencing gene expression and small molecule inhibitors on gene expression and cytotoxic effects were examined by quantitative real-time PCR and cell proliferation assay. ROS induced by androgen depletion co-localized with peroxisomes in prostate cancer cells. Among peroxisome-related genes, PPARA was commonly induced by AR inhibition and involved in ROS production via PKC signaling. Inhibition of PPARα by specific siRNA and a small molecule inhibitor suppressed cell proliferation and increased cellular sensitivity to the antiandrogen enzalutamide in prostate cancer cells. This study revealed a novel pathway by which AR inhibition induced intracellular ROS mainly in peroxisomes through PPARα activation in prostate cancer. This pathway is a promising target for the development of novel therapeutics for prostate cancer in combination with AR-targeting therapy such as antiandrogen enzalutamide. [Display omitted] • AR inhibition induced intracellular ROS mainly in peroxisomes. • AR inhibition upregulated PPARα expression in prostate cancer. • PPARα inhibition reduced intracellular ROS in prostate cancer. • PPARα inhibition suppressed prostate cancer cell proliferation. • PPARα inhibition increased cellular sensitivity to antiandrogen enzalutamide. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma
- Author
-
Tatsugami, Katsunori, Eto, Masatoshi, Harano, Masahiko, Nagafuji, Koji, Omoto, Kazuya, Katano, Mitsuo, Harada, Mine, and Naito, Seiji
- Published
- 2004
- Full Text
- View/download PDF
24. Steroidogenesis in castration-resistant prostate cancer.
- Author
-
Shiota, Masaki, Endo, Satoshi, Blas, Leandro, Fujimoto, Naohiro, and Eto, Masatoshi
- Subjects
- *
CASTRATION-resistant prostate cancer , *PROSTATE cancer , *ANDROGEN receptors , *HORMONE therapy , *ADRENAL glands - Abstract
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed. However, primary or acquired resistance to these ARPIs occurs; in turn attributable, at least in part, to the maintained androgen milieu despite intensive suppression of AR signaling similar to castration resistance. In addition to the classical pathway to produce potent androgens such as testosterone and dihydrotestosterone, the alternative pathway and the backdoor pathway which bypasses testosterone to produce dihydrotestosterone have been shown to play a role in intratumor steroidogenesis. Furthermore, the 11β-hydroxyandrostenedione pathway to produce the potent oxygenated androgens 11-ketotestosterone and 11-ketodihydrotestosterone has been suggested to be functional in prostate cancer. These steroidogenesis pathways produce potent androgens that promote tumor resistance to endocrine therapy including novel ARPIs. Here, we overview the current evidence on the pathological androgen milieu by altered metabolism and transport in prostate cancer, leading to resistance to endocrine therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system.
- Author
-
Nonami, Atsushi, Matsuo, Ryu, Funakoshi, Kouta, Nakayama, Tomohiro, Goto, Shigenori, Iino, Tadafumi, Takaishi, Shigeo, Mizuno, Shinichi, Akashi, Koichi, and Eto, Masatoshi
- Subjects
- *
PROPORTIONAL hazards models , *LYMPHOCYTES , *CARCINOGENESIS , *LONGITUDINAL method , *T cells , *T helper cells , *SURVIVAL rate , *CYTOTOXIC T cells - Abstract
This prospective clinical study aimed to determine the efficacy and prognostic factors of adoptive activated αβT lymphocyte immunotherapy for various refractory cancers. The primary endpoint was overall survival (OS), and the secondary endpoint was radiological response. The authors treated 96 patients. Activated αβT lymphocytes were infused every 2 weeks for a total of six times. Prognostic factors were identified by analyzing clinical and laboratory data obtained before therapy. Median survival time (MST) was 150 days (95% confidence interval, 105–191), and approximately 20% of patients achieved disease control (complete response + partial response + stable disease). According to the multivariate Cox proportional hazards model with Akaike information criterion–best subset selection, sex, concurrent therapy, neutrophil/lymphocyte ratio, albumin, lactate dehydrogenase, CD4:CD8 ratio and T helper (Th)1:Th2 ratio were strong prognostic factors. Using parameter estimates of the Cox analysis, the authors developed a response scoring system. The authors then determined the threshold of the response score between responders and non-responders. This threshold was able to significantly differentiate OS of responders from that of non-responders. MST of responders was longer than that of non-responders (317.5 days versus 74 days). The validity of this response scoring system was then confirmed by internal validation. Adoptive activated αβT lymphocyte immunotherapy has clinical efficacy in certain patients. The authors' scoring system is the first prognostic model reported for this therapy, and it is useful for selecting patients who might obtain a better prognosis through this modality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
- Author
-
Motzer, Robert, Porta, Camillo, Alekseev, Boris, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, and Cella, David
- Subjects
- *
RENAL cell carcinoma , *QUINOLINE , *RESEARCH , *UREA , *CLINICAL trials , *RESEARCH methodology , *ANTINEOPLASTIC agents , *MONOCLONAL antibodies , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *QUALITY of life , *RESEARCH funding - Abstract
Background: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-related quality-of-life (HRQOL) outcomes from the CLEAR study.Methods: This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries. Patients were required to be 18 years or older, with advanced clear-cell renal cell carcinoma, and a Karnofsky performance status of 70% or higher. Patients who had received previous systemic anticancer therapy for renal cell carcinoma were not eligible. Patients were randomly assigned (1:1:1) to lenvatinib (oral 20 mg per day) plus pembrolizumab (intravenous 200 mg every 21 days), lenvatinib (oral 18 mg per day) plus everolimus (oral 5 mg per day) in 21-day cycles, or sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off). Patients were assigned to treatments with a computer-generated randomisation scheme and were stratified by geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint, previously reported, was progression-free survival, and HRQOL was a secondary endpoint. Most HRQOL analyses were done in patients who underwent randomisation, received at least one dose of study treatment, and had any HRQOL data. Completion and compliance analyses were done in the full analysis set. Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and the EQ-5D-3 Level (EQ-5D-3L) preference questionnaire were administered at baseline and on day 1 of each subsequent 21-day cycle. This study is registered with ClinicalTrials.gov, NCT02811861, and is closed to new participants.Findings: Between Oct 13, 2016, and July 24, 2019, 355 patients were randomly assigned to the lenvatinib plus pembrolizumab group, 357 to the lenvatinib plus everolimus group, and 357 to the sunitinib group. Median follow-up for HRQOL analyses was 12·9 months (IQR 5·6-22·3). Because of the promising efficacy and safety results of lenvatinib plus pembrolizumab in the first-line setting, we focus the HRQOL results in this report on that combination versus sunitinib. Mean change from baseline in the lenvatinib plus pembrolizumab group compared with the sunitinib group was -1·75 (SE 0·59) versus -2·19 (0·66) for FKSI-DRS, -5·93 (0·86) versus -6·73 (0·94) for EORTC QLQ-C30 global health status/quality of life (GHS/QOL), and -4·96 (0·85) versus -6·64 (0·94) for the EQ-5D visual analogue scale (VAS). Median time to first deterioration in the lenvatinib plus pembrolizumab group compared with the sunitinib group was 9·14 weeks (95% CI 6·43-12·14) versus 12·14 weeks (9·14-15·29; HR 1·13 [95% CI 0·94-1·35], log-rank p=0·20) for FKSI-DRS, 12·00 weeks (7·29-15·14) versus 9·14 weeks (6·29-12·14; 0·88 [0·74-1·05], log-rank p=0·17) for EORTC QLQ-C30 GHS/QOL, and 9·43 weeks (6·43-12·29) versus 9·14 weeks (6·29-12·00; 0·83 [0·70-0·99], log-rank p=0·041) for the EQ-5D VAS. Median time to definitive deterioration in the lenvatinib plus pembrolizumab group compared with the sunitinib group was 134·14 weeks (95% CI 120·00-not estimable) versus 117·43 weeks (90·14-131·29; HR 0·70 [95% CI 0·53-0·92], log-rank p=0·0081) for FKSI-DRS, 114·29 weeks (102·14-153·29) versus 75·14 weeks (57·29-105·14; 0·60 [0·47-0·77], log-rank p<0·0001) for EORTC QLQ-C30 GHS/QOL, and 124·86 weeks (94·71-134·57) versus 74·86 weeks (54·14-96·00; 0·67 [0·53-0·85], log-rank p=0·0012) for the EQ-5D VAS. No outcomes on any of the instruments significantly favoured sunitinib over lenvatinib plus pembrolizumab. Most HRQOL comparisons of lenvatinib plus everolimus versus sunitinib were similar or favoured sunitinib.Interpretation: These HRQOL results demonstrate that patients given lenvatinib plus pembrolizumab treatment had similar or favourable scores compared with patients given sunitinib, particularly with respect to time to definitive deterioration. These results support the efficacy and safety profile of lenvatinib plus pembrolizumab as first-line therapy for patients with advanced renal cell carcinoma.Funding: Eisai (Nutley, NJ, USA) and Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
27. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression.
- Author
-
Iwamoto, Chika, Ohuchida, Kenoki, Shinkawa, Tomohiko, Okuda, Sho, Otsubo, Yoshiki, Okumura, Takashi, Sagara, Akiko, Koikawa, Kazuhiro, Ando, Yohei, Shindo, Koji, Ikenaga, Naoki, Nakata, Kohei, Moriyama, Taiki, Miyasaka, Yoshihiro, Ohtsuka, Takao, Eto, Masatoshi, Akashi, Koichi, and Nakamura, Masafumi
- Subjects
- *
CANCER invasiveness , *PANCREATIC cancer , *MACROPHAGES , *PANCREATIC tumors , *MESENCHYMAL stem cells , *BONE marrow - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic reaction caused by cancer-associated fibroblasts (CAFs), which provokes treatment resistance. CAFs are newly proposed to be heterogeneous populations with different functions within the PDAC microenvironment. The most direct sources of CAFs are resident tissue fibroblasts and mesenchymal stem cells, however, the origins and functions of CAF subtypes remain unclear. Here, we established allogeneic bone marrow (BM) transplantation models using spontaneous PDAC mice, and then investigated what subtype cells derived from BM modulate the tumor microenvironment and affect the behavior of pancreatic cancer cells (PCCs). BM-derived multilineage hematopoietic cells were engrafted in recipient pancreas, and accumulated at the invasive front and central lesion of PDAC. We identified BM macrophages-derived CAFs in tumors. BM-derived macrophages treated with PCC-conditioned media expressed CAF markers. BM-derived macrophages led the local invasion of PCCs in vitro and enhanced the tumor invasive growth in vivo. Our data suggest that BM-derived cells are recruited to the pancreas during carcinogenesis and that the specific subpopulation of BM-derived macrophages partially converted into CAF-like cells, acted as leading cells, and facilitated pancreatic cancer progression. The control of the conversion of BM-derived macrophages into CAF-like cells may be a novel therapeutic strategy to suppress tumor growth. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
- Author
-
Minami, Keita, Osawa, Takahiro, Kojima, Takahiro, Hara, Tomohiko, Eto, Masatoshi, Takeuchi, Ario, Nakai, Yasutomo, Ueda, Kosuke, Ozawa, Michinobu, Uemura, Motohide, Ohba, Kojiro, Tamura, Keita, Shindo, Tetsuya, Nakagomi, Hiroshi, Takahashi, Atsushi, Anai, Satoshi, Yokomizo, Akira, Morizane, Shuichi, Kimura, Takahiro, and Shimazui, Toru
- Subjects
- *
RENAL cell carcinoma , *CHRONIC kidney failure , *RENAL replacement therapy , *KIDNEY physiology , *GLOMERULAR filtration rate - Abstract
• The efficacy of axitnib is not affected by renal impairment. • Treatment outcomes including Objective response rate and Progression-free survival are were comparable among the five groups categorized according to renal function. • Among patients with an eGFR <30 mL/min, 9% required renal replacement therapy at a median of 14 (range 5–27) months after starting treatment with axitinib. Limited information is currently available on the efficacy and safety of axitinib for metastatic renal cell carcinoma (mRCC) patients with renal impairment. Therefore, the present study investigated the efficacy and toxicity of axitinib in patients with chronic kidney disease. Post-hoc analyses were performed on a Japanese multicenter cohort study of 477 mRCC patients who received axitinib followed by 1 or 2 regimens of systemic antiangiogenic therapy between January 2012 and December 2016. Differences in clinical characteristics and the efficacy and safety of axitinib were assessed based on pretreatment renal function. Patients were categorized into the following 5 renal function groups according to baseline renal function: estimated glomerular filtration rate (eGFR) ≥60 ml/min (n = 133), 45 ml/min ≤eGFR <60 ml/min (n = 153), 30 ml/min ≤eGFR< 45 ml/min (n = 130), eGFR <30 ml/min (n = 45), and dialysis (n = 16). Median progression-free survival (PFS) (95% confidence interval [CI]) in the 5 groups was 11 (8−16), 14 (11−19), 14 (10–19), 12 (8−24), and 6 (3-NR) months, respectively (p = 0.781). After adjustments for treatment-related confounders, the renal function group was not a significant prognostic factor for PFS. Objective response rates in the 5 groups were 22%, 23%, 23%, 18%, 20%, and 38%, respectively (p = 0.468). Regarding adverse events of all grades, hypertension (p = 0.0006) and renal and urinary disorders (p < 0.0001) were more frequently observed in the eGFR <30 ml/min group than in the other groups. Since renal function at the initiation of treatment with axitinib does not adversely affect the efficacy of VEGF-TKI therapy, clinicians do not need to avoid its administration to mRCC patients with impaired renal function in consideration of the risk of progression to end-stage renal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. SY13-2 Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma.
- Author
-
Inokuchi, Junichi, Goto, Shunsuke, Monji, Keisuke, and Eto, Masatoshi
- Subjects
- *
RENAL cell carcinoma , *METASTASIS - Published
- 2023
- Full Text
- View/download PDF
30. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
- Author
-
Lee, Jae-Lyun, Desai, Chirag, Park, Se Hoon, Tsuchiya, Norihiko, Su, Po-Jung, Chan, Timothy Tim Wai, Gurney, Howard, Gao, Seasea, Wang, Jing, Sandner, Robin, di Pietro, Alessandra, and Eto, Masatoshi
- Subjects
- *
TRANSITIONAL cell carcinoma , *BLADDER , *ASIANS , *SUBGROUP analysis (Experimental design) , *URINARY tract infections , *OVERALL survival - Abstract
• JAVELIN Bladder 100 studied avelumab first-line maintenance in urothelial carcinoma. • Avelumab maintenance prolonged survival in patients with urothelial carcinoma. • We report results from the Asian subgroup of JAVELIN Bladder 100. • Efficacy benefits in the Asian subgroup were consistent with the overall population. • No new safety signals specific to Asian patients were identified. The phase 3 JAVELIN Bladder 100 trial showed significantly prolonged overall survival (OS) with avelumab first-line maintenance + best supportive care (BSC) vs. BSC alone in patients with advanced urothelial carcinoma (UC) that had not progressed with first-line platinum-containing chemotherapy. Here, efficacy and safety were assessed from the initial analysis of the JAVELIN Bladder 100 trial (data cutoff October 21, 2019) in patients enrolled in Asian countries. Patients with locally advanced or metastatic UC that had not progressed with 4 to 6 cycles of first-line platinum-containing chemotherapy (gemcitabine + cisplatin or carboplatin) were randomized 1:1 to receive avelumab first-line maintenance + BSC or BSC alone, stratified by best response to first-line chemotherapy and visceral vs. nonvisceral disease when initiating first-line chemotherapy. The primary endpoint was OS assessed from randomization in all patients and patients with PD-L1+ tumors (Ventana SP263 assay). Secondary endpoints included progression-free survival (PFS) and safety. A total of 147 patients in JAVELIN Bladder 100 were enrolled in Asian countries (Hong Kong, India, Japan, South Korea, and Taiwan). In this Asian subgroup, 73 and 74 patients received avelumab + BSC or BSC alone, respectively. Median OS was 25.3 months (95% CI, 18.6 to not estimable [NE]) in the avelumab + BSC arm vs. 18.7 months (95% CI, 12.8–NE) in the BSC alone arm (hazard ratio [HR], 0.74 [95% CI, 0.43–1.26]); median PFS was 5.6 months (95% CI, 2.0–7.5) vs. 1.9 months (95% CI, 1.9–1.9), respectively (HR, 0.58 [95% CI, 0.38–0.86]). In the avelumab + BSC vs. BSC alone arms, grade ≥3 treatment-emergent adverse events (any causality) occurred in 44.4% vs. 16.2%, respectively. The most common grade ≥3 treatment-emergent adverse events in the avelumab + BSC arm were anemia (9.7%), amylase increased (5.6%), and urinary tract infection (4.2%). Efficacy and safety results for avelumab first-line maintenance in the Asian subgroup of JAVELIN Bladder 100 were generally consistent with those in the overall trial population. These data support the use of avelumab first-line maintenance as standard of care for Asian patients with advanced UC that has not progressed with first-line platinum-containing chemotherapy. NCT02603432 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
- Author
-
Takamatsu, Dai, Kiyozawa, Daisuke, Kohashi, Kenichi, Kinoshita, Fumio, Toda, Yu, Ishihara, Shin, Eto, Masatoshi, and Oda, Yoshinao
- Subjects
- *
RENAL cell carcinoma , *PROGRAMMED cell death 1 receptors , *IMMUNITY , *TUMOR-infiltrating immune cells , *ADENOSINES , *IMMUNE checkpoint inhibitors , *RENAL cancer - Abstract
One of the most aggressive forms of kidney cancer is renal cell carcinoma (RCC) with sarcomatoid changes and rhabdoid features (S/R). Adenosine produced via CD73 binds to adenosine 2 A receptor (A2AR) and suppress antitumor immunity. Here, we attempted to analyze the expression of CD73/A2AR in S/R RCC and examined its relationships with other immune microenvironments and prognostic effect. Sixty cases of S/R RCC were selected. CD73/A2AR expression levels were graded in the tumor cells or infiltrating immune cells on a score of 0–3 and divided into low (0 or 1) or high (2 or 3) groups. PD-L1 results were defined by the tumor proportion score (TPS). We counted the numbers of CD8+, FOXP3+, CD68+, and CD163+ immune cells. The rates of CD73/A2AR expression in epithelial component (23.3% and 15.0%) were lower than those in high-grade component (70.0% and 45.0%). CD73/A2AR were significantly correlated to high numbers of regulatory Tcells and macrophages of M2 subtype (CD73: P = 0.0059 and 0.0002; A2AR: P = 0.0002 and 0.018, respectively). Multivariate analysis showed that CD73/A2AR expressions were independent markers of unfavorable prognosis in S/R RCCs (P = 0.0204 and 0.0116, respectively). In RCC, the S/R component had higher expressions of CD73/A2AR than the epithelial component, and CD73/A2AR were independent prognostic factors. Compared with other RCCs, S/R RCCs are more effective at blocking adenosine signaling and CD73/A2AR inhibitors are expected to enhance the therapeutic efficacy and improve the prognosis of immune checkpoint inhibitor therapies. • The rates of CD73/A2AR expressions in the S/R components were higher than those in the epithelial component. • The S/R components showed higher rates of expression of CD73/A2AR than previously reported primary and metastatic RCCs. • CD73 and A2AR expressions were significantly correlated with high densities of FOXP3+ TILs and CD163+ TAMs. • CD73 and A2AR expressions were independent markers of an unfavorable prognosis in RCC with S/R components respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study.
- Author
-
Takamatsu, Dai, Kohashi, Kenichi, Kiyozawa, Daisuke, Kinoshita, Fumio, Ieiri, Kosuke, Baba, Masaya, Eto, Masatoshi, and Oda, Yoshinao
- Subjects
- *
RENAL cell carcinoma , *FLUORESCENCE in situ hybridization , *BIOMARKERS , *GENE rearrangement , *CLINICAL pathology , *LYSOSOMES - Abstract
It is possible that PRCCs may still contain a variety of unknown histologic subtypes. Some PRCCs express high expression of TFE3 protein without TFE3 gene rearrangement, but no reports have investigated the significance of this. Here we attempted to examine clinicopathological and molecular significance of the TFE3-immunopositive PRCC. We reviewed the histology and immunohistochemistry in 58 PRCCs. TFE3 immunoexpression was recognized in 7 cases. Because TFE3 immunostaining shows false-positive, to ensure the integrity of TFE3 immunostaining, the immunostaining was performed under strict control of internal controls and western blotting was performed on 2 positive cases and 5 negative cases, and differences in protein expression between two groups were confirmed. Significant immunohistochemical expressions of autophagy/lysosome proteins were observed in TFE3-positive group. No TFE3 gene arrangement was detected in all positive cases by fluorescence in situ hybridization. Whole-exome sequencing was performed on 6 TFE3-positive and 2 TFE3-negative cases. Gain of chromosome 7 was found in five of 6 TFE3-positive cases (83%). TFE3-positive group was correlated significantly with higher pTstage, cNstage, WHO/ISUP nuclear grade, and decreased OS. TFE3-immunopositive PRCC group had a poorer prognosis than TFE3-negative PRCC group and showed correlation with expressions of autophagy/lysosome proteins, suggesting that enhancement of autophagy/lysosome function drives an environment of energy metabolism that is favorable for cancer. It is necessary to recognize that there is TFE3-immunopositive group without TFE3 gene rearrangement within PRCC. Because of its aggressive biological behaviour, TFE3 can act as a biomarker in PRCC; moreover, autophagy-inhibiting drugs may have therapeutic effects on TFE3-immunopositive PRCC. [Display omitted] • We found that there were TFE3-immunopositive PRCCs without TFE3 gene rearrangement. • TFE3-immunopositive PRCCs correlated significantly with the expression of autophagy/lysosome proteins and a worse prognosis. • TFE3 should be considered as a surrogate marker in PRCC, and autophagy inhibitors may have therapeutic effects on TFE3-immunopositive PRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. O9-1 Updated analysis of circulating tumor DNA in advanced genitourinary cancers: SCRUM-Japan MONSTAR SCREEN Project.
- Author
-
Nonomura, Norio, Kato, Taigo, Fujisawa, Takao, Shiota, Masaki, Eto, Masatoshi, Osawa, Takahiro, Abe, Takashige, Shinohara, Nobuo, Yasumizu, Yota, Tanaka, Nobuyuki, Oya, Mototsugu, Nishimoto, Koshiro, Hayashi, Takuji, Nakayama, Masashi, Horasawa, Satoshi, Kuramoto, Naomi, Nakamura, Yoshiaki, Bando, Hideaki, Yoshino, Takayuki, and Matsubara, Nobuaki
- Subjects
- *
CIRCULATING tumor DNA , *MEDICAL screening - Published
- 2022
- Full Text
- View/download PDF
34. Enhanced Antitumor Effects of an Engineered Measles Virus Edmonston Strain Expressing the Wild-type N, P, L Genes on Human Renal Cell Carcinoma.
- Author
-
Xin Meng, Nakamura, Takafumi, Okazaki, Toshihiko, Inoue, Hiroyuki, Takahashi, Atsushi, Miyamoto, Shohei, Sakaguchi, Gaku, Eto, Masatoshi, Naito, Seiji, Takeda, Makoto, Yanagi, Yusuke, and Tani, Kenzaburo
- Subjects
- *
VIRUS diseases , *MEASLES virus , *CANCER treatment , *CANCER cells , *CELL lines - Abstract
Measles virus Edmonston strain (MV-Edm) is thought to have remarkable oncolytic activity that selectively destroys human tumor cells. The P/V/C protein of wild-type MV was shown to resist the antiviral effects of interferon (IFN)-α. Here, we engineered new MVs by arming MV-Edm tag strain (a V-defective vaccine-lineage strain, MV-Etag) with the P or N, P, and L genes of wild-type MV (MV-P and MV-NPL, respectively). The oncolytic activities of the MVs were determined in human renal cell carcinoma (RCC) cell lines and primary human RCC cells by the MTT assay. The antitumor efficacy of the MVs was evaluated in A-498 xenografts in nude mice. IFN-α effectively inhibited the replication of MV-Etag and MV-P, but not MV-NPL. MV-NPL more efficiently induced cytopathic effects (CPEs) in OS-RC-2 cells, even in the presence of human IFN-α. MV-NPL replicated more rapidly than MV-P and MV-Etag in A-498 cells. Apoptosis was induced earlier in A-498 cells by MV-NPL than MV-Etag and MV-P. MV-NPL showed more significant antitumoral effects and had prolonged replication compared to MV-Etag and MV-P. In this study, we demonstrated that the newly engineered MV-NPL has more effective oncolytic activity and may help establish an innovative cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
35. Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4
- Author
-
Takeuchi, Ario, Kamiryou, Yoriyuki, Yamada, Hisakata, Eto, Masatoshi, Shibata, Kensuke, Haruna, Kennichi, Naito, Seiji, and Yoshikai, Yasunobu
- Subjects
- *
ORAL medicine , *DRUG administration , *XANTHAN gum , *ANTINEOPLASTIC agents , *POLYSACCHARIDES , *PHYTOPATHOGENIC bacteria , *CELL receptors , *XANTHOMONAS campestris - Abstract
Abstract: Purpose: Xanthan gum (XG) is a complex exopolysaccharide produced by the plant-pathogenic bacterium Xanthomonas campestris pv. and is widely used as a thickener or viscosifier. We examined in this study the antitumor effects of XG. Experimental design: Cytokine production by XG-stimulated murine macrophage cell lines, J772 and RAW264.7, and peritoneal adherent cells from wild type C57BL/6 mice, TLR2 or MyD88-deficient mice, C3H/HeN, and TLR4-mutant C3H/HeJ mice were examined. In order to examine in vivo antitumor effects of XG, mice were inoculated subcutaneously with tumor cells and administered orally with XG once every 5days from 1day before the tumor inoculation. Tumor growth, mouse survival, NK activity, and tumor-specific cytotoxicity were examined. Results: In vitro culture with XG induced interleukin-12 and tumor necrosis factor-alpha production from macrophages. XG stimulated macrophages in a MyD88-dependent manner and was mainly recognized by Toll-like receptor 4 (TLR4). Oral administration of XG significantly retarded tumor growth and prolonged survival of the mice inoculated subcutaneously with B16Kb melanoma cells. NK activity as well as tumor-specific cytotoxicity of CD8 T cells was augmented in the XG-treated mice. The in vivo antitumor effects of XG were also dependent on TLR-4, as C3H/HeJ mice, which lack TLR4 signaling, exhibited no effect of XG on the growth of syngeneic bladder tumor, MBT-2. Conclusion: These results suggest beneficial effects of oral administration of XG on immune-surveillance against neoplasms. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. Molecular mechanisms regulating urogenital expression of nitric oxide synthase in spontaneously hypertensive rats
- Author
-
Yono, Makoto, Yoshida, Masaki, Yamamoto, Yasuhiro, Imanishi, Aya, Fukagawa, Atsushi, Latifpour, Jamshid, and Eto, Masatoshi
- Subjects
- *
MOLECULAR biology , *GENETIC regulation , *NITRIC-oxide synthases , *HYPERTENSION , *ANIMAL models in research , *DOXAZOSIN , *REVERSE transcriptase polymerase chain reaction , *LABORATORY rats - Abstract
Abstract: Aims: Although doxazosin, but not nifedipine, can partially prevent a decrease in urogenital expression of nitric oxide synthase (NOS) in spontaneously hypertensive rats (SHRs), the mechanisms involved in the regulated expression of NOS are not known. Therefore, we identified differential gene expression profiles in SHRs to elucidate the molecular mechanisms regulating urogenital expression of NOS. Main methods: SHRs and normotensive Wistar–Kyoto (WKY) rats received doxazosin (30 mg/kg/day) or nifedipine (30 mg/kg/day) orally for 4 weeks. Microarray expression data of key transcripts were verified by real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis. Key findings: RT-PCR data, in accord with the microarray analysis, indicated that untreated SHRs had lower mRNA expression levels of cAMP responsive element binding protein 1 (Creb1) in the pelvic ganglion and vascular endothelial growth factor A (Vegfa) and kinase insert domain protein receptor (Kdr) in the penis, and higher mRNA expression levels of brain derived neurotrophic factor and neurotrophin 3 (Ntf3) in the bladder and Ntf3, Rho-kinases (Rock1 and Rock2) and caveolin 1 (Cav1) in the penis than untreated WKY rats. In SHRs, doxazosin and nifedipine caused a significant decrease in penile expression of Rock1 and Rock2, whereas the differential alterations in urogenital expression of Creb1, Vegfa, Kdr and Cav1 were attenuated by treatment with doxazosin, but not nifedipine. Significance: Our data suggest that differential alterations in the expression of several genes related to pathways that mediate NOS expression in the urogenital tissues of SHRs, which can be attenuated by doxazosin treatment, may play an important role in regulating urogenital expression of NOS. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
37. The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study.
- Author
-
Nagakawa, Shohei, Shiota, Masaki, Fujimoto, Naohiro, Yamamoto, Yoshiaki, Blas, Leandro, Tsukahara, Shigehiro, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Uchiumi, Takeshi, Matsuyama, Hideyasu, and Eto, Masatoshi
- Subjects
- *
BLADDER cancer , *GENOME-wide association studies , *CANCER invasiveness , *SINGLE nucleotide polymorphisms , *GENETIC variation , *MEDICAL research - Abstract
Objective: Bacillus Calmette-Guérin (BCG) instillation therapy is widely used to reduce intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). In this study, we aimed to reveal the genetic variations associated with intravesical recurrence after BCG therapy for NMIBC in a genome-wide association study (GWAS).Materials and Methods: This study included Japanese patients with NMIBC, in whom genomic DNA was obtained from whole blood samples. The association between genetic variation and treatment failure was analyzed by GWAS in 44 patients treated with BCG instillation as a discovery cohort. Candidate single-nucleotide polymorphisms (SNPs) were examined separately in 47 patients treated with BCG instillation and in 62 patients treated with chemotherapeutic agent instillation as validation studies.Results: Among the 44 patients in the discovery cohort, 14 cases experienced intravesical recurrent diseases. GWAS identified 12 candidate SNPs (rs9374832, rs35176001, rs363765, rs2127120, rs4277759, rs73664140, rs1607282, rs12141654, rs4541358, rs6986852, rs12373386, and rs17637903). In the validation study, a genetic risk stratification model using the number of risk alleles in rs363765 and rs6986852 discriminated the risk of intravesical recurrence after BCG therapy, but not after non-BCG therapy.Conclusion: This study suggested that several SNPs were associated with intravesical recurrence after BCG therapy for NMIBC. A genetic risk model may be useful to predict intravesical recurrence after BCG therapy, warranting further research and development for clinical application. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
38. PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN.
- Author
-
Nonomura, Norio, Kato, Taigo, Fujisawa, Takao, Shiota, Masaki, Eto, Masatoshi, Osawa, Takahiro, Abe, Takashige, Shinohara, Nobuo, Yasumizu, Ryota, Tanaka, Nobuyuki, Oya, Mototsugu, Nishimoto, Koshiro, Horasawa, Satoshi, Kuramoto, Naomi, Nakamura, Yoshiaki, Taniguchi, Hiroya, Yoshino, Takayuki, and Matsubara, Nobuaki
- Subjects
- *
CIRCULATING tumor DNA , *GENITOURINARY organ cancer - Published
- 2021
- Full Text
- View/download PDF
39. Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.
- Author
-
Machidori, Asako, Shiota, Masaki, Kobayashi, Satoshi, Matsumoto, Takashi, Monji, Keisuke, Kashiwagi, Eiji, Takeuchi, Ario, Takahashi, Ryosuke, Inokuchi, Junichi, and Eto, Masatoshi
- Subjects
- *
BLOOD cell count , *CASTRATION-resistant prostate cancer , *PROSTATE cancer patients , *ANDROGEN receptors , *LEUKOCYTE count , *OVERALL survival , *STEROID drugs , *ANTIANDROGENS , *HYDANTOIN , *ORGANIC compounds , *PROGNOSIS , *RETROSPECTIVE studies , *BENZAMIDE , *PROSTATE tumors - Abstract
Background: This study investigated the prognostic significance of complete blood count data in castration-resistant prostate cancer patients treated using androgen receptor pathway inhibitors (ARPIs).Patients and Methods: Patients treated with an ARPI, abiraterone or enzalutamide, as first-line therapy for castration-resistant prostate cancer from 2014 to 2018 were included. The association between complete blood count data and prognoses including progression-free survival and overall survival (OS) was investigated.Results: High white blood cell counts (Conclusion: We found that white blood cell counts and neutrophil-to-lymphocyte ratios may be prognostic for progression-free survival while red cell distribution widths may be prognostic for OS. In particular, a low Hb level was a robust prognostic factor for poor OS. These findings could be useful in predicting prognosis in CRPC patients treated with ARPIs. [ABSTRACT FROM AUTHOR] - Published
- 2021
- Full Text
- View/download PDF
40. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
- Author
-
Ieiri, Kosuke, Shiota, Masaki, Kashiwagi, Eiji, Takeuchi, Ario, Takahashi, Ryosuke, Inokuchi, Junichi, Iwai, Hidenori, Shiga, Ken-ichiro, Yokomizo, Akira, Yoshitake, Tadamasa, Shioyama, Yoshiyuki, Ishigami, Kousei, Terashima, Hiromi, and Eto, Masatoshi
- Subjects
- *
LYMPH nodes , *PROGNOSIS , *RADIOTHERAPY , *LYMPHATIC metastasis , *PROGRESSION-free survival , *PROSTATE cancer , *PATIENT selection , *METASTASIS , *RETROSPECTIVE studies , *PROSTATE tumors - Abstract
Background: This study aimed to identify the prognostic and predictive factors of local radiotherapy in clinically regional lymph node-positive prostate cancer.Patients and Methods: This study includes patients who were newly diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017. We investigated the prognostic value of clinicopathological parameters for progression-free survival (PFS) and overall survival (OS) as well as the differential prognostic impact of radiotherapy by subgroup analysis.Results: Among the 93 men enrolled as patients, 48 (51.6 %) were treated with radiotherapy. The biopsy positive core rate and biopsy Gleason score were associated with PFS, and the number of lymph node metastases was associated with both PFS and OS. Patients who underwent radiotherapy showed better PFS and OS. High-risk features (at least 2 criteria among ≥75% biopsy positive core rate, Gleason score ≥9, and ≥2 positive lymph nodes) were especially associated with improved outcomes after undergoing radiotherapy.Conclusion: We identified prognostic factors for clinically regional lymph node-positive prostate cancer and showed the benefits of local radiation therapy. Patients with high-risk features may be especially suitable candidates for radiotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
41. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
- Author
-
Shiota, Masaki, Endo, Satoshi, Fujimoto, Naohiro, Tsukahara, Shigehiro, Ushijima, Miho, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Uchiumi, Takeshi, and Eto, Masatoshi
- Subjects
- *
CASTRATION-resistant prostate cancer , *SINGLE nucleotide polymorphisms , *TESTOSTERONE , *ANDROGENS , *METABOLISM , *GENETIC polymorphisms , *ANTIANDROGENS , *PROGNOSIS , *RETROSPECTIVE studies , *PROSTATE tumors - Abstract
Objective: Androgen metabolism is a key component in therapeutic resistance to androgen deprivation therapy (ADT). This study aimed to reveal the significance of genetic polymorphisms in genes involved in androgen metabolism, including CYP17A1, AKR1C3, and HSD17B, on serum testosterone levels during ADT, as well as the prognosis of men undergoing ADT for metastatic prostate cancer (CaP).Materials and Methods: This study included 104 Japanese patients with metastatic CaP, for whom serum testosterone data during ADT were available for 80 patients. The association of CYP17A1 (rs743572), AKR1C3 (rs12529), HSD17B1 (rs605059), HSD17B3 (rs2066479), and HSD17B4 (rs7737181) with serum testosterone levels during ADT and prognosis (progression-free survival and overall survival) was examined. Enzymatic activity in AKR1C3 H5Q was examined using recombinant protein.Results: Homozygous wild-type (GG allele; median [interquartile range], 12.0 ng/ml [8.0-19.0 ng/ml]) AKR1C3 rs12529 was associated with higher serum testosterone levels during ADT compared with variant-type (GC/CC alleles; median [interquartile range], 9.0 ng/ml [6.4-10.8 ng/ml]). Consistently, variant-type (GC/CC alleles) AKR1C3 rs12529 showed significantly lower risk of progression (hazard ratio [95% confidence interval], 0.47 [0.24-0.96], P = 0.039) compared with homozygous wild-type (GG allele) on multivariate analysis. Meanwhile, other genetic variations were associated with neither serum testosterone during ADT nor prognosis. Enzyme activity of wild-type AKR1C3 was comparable to the H5Q mutant.Conclusions: Taken together, this study demonstrated that AKR1C3 polymorphism, which was associated with serum testosterone levels during ADT, may be a prognostic factor of the progression to castration-resistant prostate cancer in Japanese men with metastatic CaP. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
42. Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.
- Author
-
Shiota, Masaki, Kobayashi, Takeshi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, and Eto, Masatoshi
- Subjects
- *
CASTRATION-resistant prostate cancer , *ANTIHYPERTENSIVE agents , *ANDROGEN receptors , *PROSTATE-specific antigen , *GLEASON grading system - Abstract
Purpose: Comorbidity with hypertension (HTN) may affect the outcome of castration-resistant prostate cancer (CRPC). In this study, we evaluated the prognostic impact of antihypertensive agents in patients with CRPC treated with androgen receptor axis-targeting (ARAT) agents or docetaxel chemotherapy.Patients and Methods: This study included 156 Japanese men with CRPC who were treated with ARAT agents (n = 85) or docetaxel (n = 71) at our hospital between 2008 and 2017. Associations between clinicopathological factors, HTN status, progression-free survival (PFS) and overall survival (OS) were evaluated by univariate and multivariate analysis.Results: When adjusted for age, prostate-specific antigen levels at pretreatment, Gleason score, and clinical M-stage, comorbid HTN was significantly associated with better OS (hazards ratio, 95% confidence interval: 0.41, 0.21-0.77; P = 0.0051), but not with PFS (hazards ratio, 95% confidence interval: 0.64, 0.38-1.11; P = 0.11) in patients treated with ARAT agent. However, HTN was not associated with PFS or OS for patients treated with docetaxel.Conclusions: Use of antihypertensive agents has prognostic significance for patients with CRPC treated with ARAT agent, but not docetaxel. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
43. P2-183 Primary tumor resection after nivolumab treatment for metastatic renal cell carcinoma: A case report.
- Author
-
Tanegashima, Tokiyoshi, Tsukahara, Shigehiro, Ikenoue, Takashi, Otsubo, Satoshi, Hasehawa, Shuji, Nishikawa, Hiroyoshi, and Eto, Masatoshi
- Subjects
- *
RENAL cell carcinoma , *PULMONARY fibrosis , *TUMORS , *PROTEIN-tyrosine kinase inhibitors , *NIVOLUMAB - Abstract
Background Several immune checkpoint blockades (ICBs) such as anti-CTLA-4 monoclonal antibody (mAb) and anti-PD-1 mAb are in clinical use. In renal cell carcinoma (RCC), it is indicated that anti-PD-1 mAb nivolumab is effective for patients who received antiangiogenic therapy regimens. However, efficacy of nivolumab as a neoadjuvant therapy has not been indicated. We report the case in which nivolumab was effective for the lung metastatic lesions of renal cell carcinoma and we could resect the primary tumor. Case presentation A 69-year-old woman was referred to our hospital and diagnosed as metastatic left RCC, cT3aN0M1 (multiple lung metastasis), cStageIV. After sequential treatment with TKIs and mTOR inhibitor, nivolumab was administered as the fifth treatment. Drug induced interstitial pneumonia occurred 6 days after the initial administration, so nivolumab was not administered thereafter. In course of 4 months, the lung metastatic lesions sharply reduced and we could resect the primary tumor. In addition, we analyzed tumor infiltrated lymphocytes (TILs) in this case with flow cytometry and compared with the other 20 tumors resected from September 2017 to May 2018 in Kyushu university hospital. The phenotype of TILs in stagIV RCC after nivolumab administration was close to those of low stage RCC. Conclusion Currently, nivolumab treatment as a neoadjuvant therapy for metastatic RCC is not common. We report a metastatic RCC case in which we resected primary tumor after administration of nivolumab and analyzed TILs with flow cytometry. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
- Author
-
Shiota, Masaki, Kashiwagi, Eiji, Murakami, Tomohiko, Takeuchi, Ario, Imada, Kenjiro, Inokuchi, Junichi, Tatsugami, Katsunori, and Eto, Masatoshi
- Subjects
- *
CASTRATION-resistant prostate cancer , *ANDROGEN receptors , *ANDROGENS , *PROSTATE , *PROSTATE cancer - Abstract
Purpose: Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC.Patients and Methods: The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined.Results: Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively.Conclusions: The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
45. Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.
- Author
-
Bigot, Pierre, Bernhard, Jean-Christophe, Flamand, Vincent, Gill, Inderbir, Verhoest, Grégory, Beauval, Jean Baptiste, Nouhaud, François Xavier, Suer, Evren, Ploussard, Guillaume, Hetet, Jean François, Rigaud, Jérôme, Baco, Eduard, Larré, Stéphane, Sebe, Philippe, Koutlidis, Nicolas, Descazeaud, Aurélien, Eto, Masatoshi, Doerfler, Arnaud, Roupret, Morgan, and Vuong, Nam Son
- Subjects
- *
RENAL cell carcinoma , *CANCER treatment , *ONCOLOGIC surgery , *SURGICAL site , *METASTASIS , *CANCER relapse , *CARCINOGENESIS , *COMPARATIVE studies , *KIDNEY tumors , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *SURVIVAL , *THERAPEUTICS , *EVALUATION research , *RETROSPECTIVE studies , *NEPHRONS , *SURGERY - Abstract
Objective: To evaluate the oncologic outcomes of nephron-sparing surgery (NSS) for localized chromophobe renal cell carcinoma (cRCC).Material and Methods: We performed a multicenter international study involving the French Network for Research on Kidney Cancer (UroCCR) and 5 international teams. Data from 808 patients treated with NSS between 2004 and 2014 for non-clear cell RCCs were analyzed.Results: We included 234 patients with cRCC. There were 123 (52.6%) females. Median age was 61 (23-88) years. Median tumor size was 3 (1-11)cm. A positive surgical margin was identified in 14 specimens (6%). Pathologic stages were T1, T2, and T3a in 202 (86.3%), 9 (3.8%), and 23 (9.8%) cases, respectively. After a mean follow-up of 46.6 ± 36 months, 2 (0.8%) patients experienced a local recurrence. No patient had metastatic progression, and no patient died from cancer. Three-years estimated cancer-free survival and cancer-specific survival were 99.1% and 100%, respectively.Conclusion: Oncological results of NSS for localized cRCC are excellent. In this series, only 2 patients had a local recurrence, and no patient had metastatic progression or died from cancer. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.